Condition
Metastatic Nasopharyngeal Cancer
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Unknown1
Active Not Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03813394Phase 1Active Not Recruiting
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
NCT05385926Phase 2RecruitingPrimary
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
NCT05198479Phase 2UnknownPrimary
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
NCT03007836Phase 1CompletedPrimary
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
Showing all 4 trials